Amplia Therapeutics Ltd ATX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- A$0.11
- Day Range
- A$0.10–0.11
- 52-Week Range
- A$0.10–0.28
- Bid/Ask
- A$0.10 / A$0.11
- Shares Outstanding
- 513.31M
- Market Cap
- A$51.33M
- Volume/Avg
- 280,143 / 794,115
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- —
- Website
- https://www.ampliatx.com
Valuation
|
Metric
|
ATX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.30 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ATX
Financial Strength
|
Metric
|
ATX
|
|---|---|
Quick Ratio | 19.54 |
Current Ratio | 19.78 |
Interest Coverage | — |
Quick Ratio
ATX
Profitability
|
Metric
|
ATX
|
|---|---|
Return on Assets (Normalized) | — |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | — |
Return on Assets
ATX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|@G&>tTG | LOCK|!$&&C | $129B | |||
| Moderna Inc
MRNA
| LOCK|>&hNgv | LOCK|$K | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|pXQ&v% | LOCK|lX?% | $79B | |||
| argenx SE ADR
ARGX
| LOCK|>ZdFH< | LOCK|b$ | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|#L&N%S | LOCK|CC$ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|XV>C#$ | LOCK|ZDSK | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|JstkB$s | LOCK|Vph> | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|Kq$jc$ | LOCK|Vtl | $24B | |||
| Incyte Corp
INCY
| LOCK|rSt^@b# | LOCK|n&$ | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|%q>kk?? | LOCK|>&# | $14B |
United States